moxetumomab pasudotox   Click here for help

GtoPdb Ligand ID: 7675

Synonyms: CAT-8015 | GCR-8015 | HA22 | Lumoxiti® | moxetumomab pasudotox-tdfk
Approved drug Immunopharmacology Ligand
moxetumomab pasudotox is an approved drug (FDA (2018), EMA (2021))
Compound class: Antibody
Comment: Peptide sequence information for this antibody is available from its IMGT/mAb-DB link. The moxetumomab monoclonal has been mutated to increase affinity for CD22 [6] (patent WO2003027135[1]), and the antibody is fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) [2,4] (patent US7982011 [5]). The Uniprot accession for Pseudomonas exotoxin-A is P11439.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Moxetumomab pasudotox was assessed as a potential treatment for B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and hairy cell leukemia [3]. Click here to view's listing of moxetumomab pasudotox trials. FDA approval for hairy cell leukemia was granted in 2018. In the EU, the antibody has had EMA orphan designation for the treatment of B-lymphoblastic leukaemia / lymphoma since 2013.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells.This targets the toxin moiety, PE38, directly to tumor cells. Internalized PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2) [7].
External links Click here for help